AbbVie Files 8-K/A: Director Changes and Officer Compensation
Ticker: ABBV · Form: 8-K/A · Filed: 2024-05-08T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, director-change, officer-compensation
Related Tickers: ABBV
TL;DR
AbbVie's 8-K/A confirms director changes and officer comp details from Feb 14.
AI Summary
AbbVie Inc. filed an 8-K/A on May 8, 2024, to amend a previous filing concerning the departure of Director Robert L. Parkinson Jr. and the election of Director Richard A. Gonzalez, effective February 14, 2024. The amendment also addresses compensatory arrangements for certain officers and the submission of matters to a vote of security holders.
Why It Matters
This filing provides updated information on corporate governance changes at AbbVie, including director transitions and details on executive compensation, which are important for investors to understand the company's leadership and incentive structures.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, primarily providing updated information on corporate governance and officer compensation, which typically carries a low risk.
Key Players & Entities
- AbbVie Inc. (company) — Filer
- Robert L. Parkinson Jr. (person) — Departing Director
- Richard A. Gonzalez (person) — Elected Director
- February 14, 2024 (date) — Effective date of director changes
- May 8, 2024 (date) — Filing date of 8-K/A
FAQ
What specific items are being amended in this 8-K/A filing?
This 8-K/A amends previous filings related to the departure of Director Robert L. Parkinson Jr., the election of Director Richard A. Gonzalez, compensatory arrangements of certain officers, and the submission of matters to a vote of security holders.
When were the director changes effective?
The changes regarding the departure of Robert L. Parkinson Jr. and the election of Richard A. Gonzalez were effective as of February 14, 2024.
Who is the filer of this document?
The filer is AbbVie Inc.
What is the filing date of this amended report?
This 8-K/A was filed on May 8, 2024.
What is the Central Index Key (CIK) for AbbVie Inc.?
The Central Index Key for AbbVie Inc. is 0001551152.
From the Filing
0001104659-24-058808.txt : 20240508 0001104659-24-058808.hdr.sgml : 20240508 20240508170046 ACCESSION NUMBER: 0001104659-24-058808 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240214 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24927280 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K/A 1 tm2413796d1_8ka.htm FORM 8-K/A false 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2024-02-14 2024-02-14 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-02-14 2024-02-14 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2024-02-14 2024-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549       FORM 8-K/A (AMENDMENT NO. 1)   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 14, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange 1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B